Alkermes (ALKS)
(Delayed Data from NSDQ)
$26.59 USD
-0.52 (-1.92%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $26.52 -0.07 (-0.26%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.59 USD
-0.52 (-1.92%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $26.52 -0.07 (-0.26%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to About Alkermes (ALKS) stock based on the movements in the options market lately.
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.
Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of -25.42% and 2.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Deciphera Pharmaceuticals (DCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
by Zacks Equity Research
Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.
Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release
by Zacks Equity Research
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
by Zacks Equity Research
Alkermes (ALKS) reports positive top-line data from a phase Ib, proof-of-concept study investigating ALKS 2680 for the treatment of narcolepsy.
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Alkermes (ALKS) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Alkermes (ALKS) Stock Moves -0.45%: What You Should Know
by Zacks Equity Research
In the most recent trading session, Alkermes (ALKS) closed at $28.75, indicating a -0.45% shift from the previous trading day.
3 Reasons Why Alkermes (ALKS) Is a Great Growth Stock
by Zacks Equity Research
Alkermes (ALKS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why Alkermes (ALKS) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Alkermes (ALKS) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Alkermes (ALKS) Outpaced the Stock Market Today
by Zacks Equity Research
Alkermes (ALKS) concluded the recent trading session at $29.45, signifying a +1.76% move from its prior day's close.
Alkermes (ALKS) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Alkermes (ALKS) stood at $29.69, denoting a -0.37% change from the preceding trading day.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why Alkermes (ALKS) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Alkermes' (ALKS) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Alkermes' (ALKS) earnings and revenues outpace estimates in the fourth quarter of 2023. Strong growth in proprietary products drives year-over-year revenues.